Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) and Incannex Healthcare (NASDAQ:IXHL – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Volatility and Risk
Eton Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7, indicating that its stock price is 600% more volatile than the S&P 500.
Valuation and Earnings
This table compares Eton Pharmaceuticals and Incannex Healthcare”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eton Pharmaceuticals | $141.06 million | 13.07 | -$4.60 million | $1.51 | 42.34 |
| Incannex Healthcare | $90,000.00 | 274.71 | -$19.30 million | ($1.69) | -1.17 |
Eton Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Eton Pharmaceuticals and Incannex Healthcare, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eton Pharmaceuticals | 0 | 1 | 5 | 0 | 2.83 |
| Incannex Healthcare | 2 | 0 | 1 | 0 | 1.67 |
Eton Pharmaceuticals presently has a consensus price target of $79.75, indicating a potential upside of 24.75%. Incannex Healthcare has a consensus price target of $18.00, indicating a potential upside of 813.71%. Given Incannex Healthcare’s higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than Eton Pharmaceuticals.
Profitability
This table compares Eton Pharmaceuticals and Incannex Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eton Pharmaceuticals | 35.35% | 104.82% | 43.09% |
| Incannex Healthcare | N/A | -19.86% | -18.80% |
Institutional & Insider Ownership
27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 9.1% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Eton Pharmaceuticals beats Incannex Healthcare on 11 of the 14 factors compared between the two stocks.
About Eton Pharmaceuticals
Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.
About Incannex Healthcare
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing investigational medicines, including cannabinoid-based combination therapies and psychedelic-assisted treatments. Its research focuses on conditions with significant unmet medical needs; its products are in development and are not established as approved treatments. The company’s pipeline has included IHL-42X, a combination of dronabinol and acetazolamide being studied for obstructive sleep apnea, as well as programs targeting inflammatory conditions and traumatic brain injury.
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
